[HTML][HTML] Angiotensin-converting enzyme and heart failure
S Álvarez-Zaballos, M Martínez-Sellés - Frontiers in Bioscience …, 2023 - imrpress.com
Pharmacotherapy is the cornerstone treatment for patients with heart failure (HF) that uses
drugs targeting the renin-angiotensin-aldosterone system (RAAS), including angiotensin …
drugs targeting the renin-angiotensin-aldosterone system (RAAS), including angiotensin …
Clinical and socioeconomic determinants of angiotensin receptor-neprilysin inhibitor prescription at hospital discharge in patients with heart failure with reduced …
JS Tran, MG Loveland, A Alamer, IL Piña… - Circulation: Heart …, 2022 - Am Heart Assoc
Background: Angiotensin receptor-neprilysin inhibitor (ARNI) prescription in the United
States remains suboptimal despite strong evidence for efficacy and value in heart failure …
States remains suboptimal despite strong evidence for efficacy and value in heart failure …
[HTML][HTML] Trajectories of sacubitril/valsartan adherence among Medicare beneficiaries with heart failure
Background Sacubitril/valsartan, an angiotensin receptor/neprilysin inhibitor (ARNi),
improves heart failure (HF) outcomes, yet real-world adherence patterns are not well …
improves heart failure (HF) outcomes, yet real-world adherence patterns are not well …
Sacubitril/valsartan versus valsartan initiation in patients naïve to renin–angiotensin system inhibitors: Insights from PARAGLIDE‐HF
N Nouhravesh, AH Gunn, D Cyr… - European Journal of …, 2025 - Wiley Online Library
Aims Whether prior treatment with angiotensin‐converting enzyme inhibitors (ACEi) or
angiotensin receptor blockers (ARBs) modifies efficacy and safety of sacubitril/valsartan …
angiotensin receptor blockers (ARBs) modifies efficacy and safety of sacubitril/valsartan …
High long-term mortality in ischaemic heart disease accentuated among ethnic minorities in Eastern Europe: findings from a prospective all-comers percutaneous …
PA Călburean, P Grebenișan, IA Nistor… - J Epidemiol …, 2024 - jech.bmj.com
Background Long-term outcomes in cardiovascular diseases are historically under-reported
in Eastern Europe. Our aim was to report long-term survival and to identify survival …
in Eastern Europe. Our aim was to report long-term survival and to identify survival …